2,6-二溴吡啶-4-羧酸 | 2016-99-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,6-二溴吡啶-4-羧酸
• 中文别名: 2,6-二溴异烟酸；2,6-二溴吡啶-3-羧酸；2,6-二溴烟酸；2,6-二溴吡啶-4-甲酸；2,6-二溴吡啶异烟酸；2,6-二溴-4-吡啶甲酸
• 英文名称: 2,6-dibromoisonicotinic acid
• 英文别名: 2,6-dibromopyridine-4-carboxylic acid；4-carboxy-2,6-dibromopyridine
• CAS: 2016-99-1
• 化学式: C₆H₃Br₂NO₂
• 分子量: 280.903
• InChiKey: AULQTVXAKNKCCA-UHFFFAOYSA-N

物化性质

• 熔点：
  184-185 °C(Solv: water (7732-18-5))
• 沸点：
  487.5±45.0 °C(Predicted)
• 密度：
  2.202±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,6-Dibromopyridine-4-carboxylic acid
Synonyms: 2,6-Dibromoisonicotinic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,6-Dibromopyridine-4-carboxylic acid
CAS number: 2016-99-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H3Br2NO2
Molecular weight: 280.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,6-二溴吡啶-4-羧酸 在 硫酸 、 sodium methylate 作用下， 反应 53.0h， 生成 2-溴-6-甲氧基-4-吡啶羧酸甲酯
  参考文献：
  名称：

  使用经由亚氨基的级联自由基环化反应合成杂芳烃。

  摘要：

  涉及均相芳族取代的级联自由基环化已用于合成新的四环。用Me（3）Sn处理乙烯基碘自由基的前体。自由基（来自六甲基二锡）产生中间体乙烯基，其经过5-外环环化到适当放置的腈基上以产生中间体亚氨基自由基。亚氨基通过6-内-环化（或5-exo环化，然后进行新细胞重排）经历芳族均质取代，并且在H-提取步骤中损失氢（H.）。我们建议这种抽象是由三叔丁基锡（Me（3）Sn。）分解产生的二叔丁基过氧化物或甲基自由基中的叔丁氧基（t-BuO。）自由基促进的。使用新方法合成了具有生物活性的生物碱生物碱苦瓜碱和荧光素A。

  DOI：

  10.1039/b501509j
• 作为产物：
  描述：

  柠嗪酸 在 sodium hydroxide 、 溴 、 phosphorus pentoxide 、 三溴化磷 作用下， 以 四氢呋喃 为溶剂， 反应 12.5h， 生成 2,6-二溴吡啶-4-羧酸
  参考文献：
  名称：

  6,6'-Dibromo-4,4'-di（hexoxymethyl）-2,2'-bipyridine：一种新的增溶砌块，用于大分子和超分子应用

  摘要：

  尽管对于配体设计和大分子或超分子应用而言，溴化联吡啶和三联吡啶是非常合乎需要的合成构件，但是已经报道了很少有这样的合成前体包括急需的增溶基团。此处报道的是一条廉价的路线，该路线可从柑桔酸制备2,6-二溴-4-（己氧基甲基）吡啶，总收率为44％，且有效转化率（60％）转化为6,6'-dibromo-4,4'-二（己氧基甲基）-2,2'-联吡啶通过氧化偶合。

  DOI：

  10.1021/jo060557i

文献信息

• [EN] 6-(MORPHOLIN-4-YL)-PYRIDIN-2-YL-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS M-TOR INHIBITORS<br/>[FR] DÉRIVÉS DE 6-(MORPHOLIN-4-YL)-PYRIDIN-2-YL-1H-PYRROLO[3,2-B]PYRIDINE EN TANT QU'INHIBITEURS DE M-TOR
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019115640A1

  公开（公告）日：2019-06-20

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

  该发明涉及式(I)的化合物，其中R1、R2、R3、R4、L和A如描述和索赔中所定义，或其药学上可接受的盐，具有mTOR激酶抑制剂活性。该发明还涉及包括式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗中使用式(I)的化合物或其药学上可接受的盐，包括治疗需要mTOR激酶抑制剂活性的疾病或症状，特别是治疗特发性肺纤维化。
• [EN] PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE MTOR DE PYRIDYLE OU DE PYRIMIDYLE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2020249652A1

  公开（公告）日：2020-12-17

  The invention relates to compounds or pharmaceutically acceptable salts thereof of formula (I): (I) wherein R1, R2, R3, R4, R4' and R5 are as defined in the description and claims; and compounds or pharmaceutically acceptable salts thereof of formulas (II), (IIa), (IIb), (IIc), and (III) having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions which include a compound of formula (I), (II), (IIa), (IIb), (IIc), or (III) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I), (II), (IIa), (IIb), (IIc), or (III), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

  该发明涉及化合物或其药用可接受盐的公式(I)：（I）其中R1、R2、R3、R4、R4'和R5如描述和索赔中定义；以及具有mTOR激酶抑制剂活性的公式(II)、(IIa)、(IIb)、(IIc)和(III)的化合物或其药用可接受盐。该发明还涉及包括公式(I)、(II)、(IIa)、(IIb)、(IIc)或(III)的化合物或其药用可接受盐的药物组合物，以及在治疗中使用公式(I)、(II)、(IIa)、(IIb)、(IIc)或(III)的化合物或其药用可接受盐，包括治疗需要mTOR激酶抑制剂活性的疾病或症状，特别是治疗特发性肺纤维化。
• MizorokiHeck and Sonogashira Cross-Couplings Catalyzed by CNC Palladium Pincer Complexes in Organic and Aqueous Media
  作者：Raul SanMartin、Blanca Inés、María Jesús Moure、María Teresa Herrero、Esther Domínguez

  DOI：10.1002/hlca.201100503

  日期：2012.6

  The catalytic activity of two CNC palladium pincer complexes is evaluated in two fundamental CC bond‐forming reactions: MizorokiHeck and Sonogashira cross‐couplings. After several optimization attempts and a brief comparison with a PCN pincer catalyst, a number of arylated alkenes and diarylethynes are synthesized by procedures based on the catalytic use of the above mentioned CNC Pd pincers in H2O

  两台数控钯钳形络合物的催化活性在两个基本C被评价 C键形成反应：Mizoroki 的Heck和的Sonogashira交叉偶联。经过几次优化尝试并与PCN夹钳催化剂进行了简要比较之后，根据上述CNC Pd夹钳在H 2 O和DMF中的催化使用方法，合成了许多芳基化烯烃和二芳基乙炔。
• Insights into the Role of New Palladium Pincer Complexes as Robust and Recyclable Precatalysts for Suzuki-Miyaura Couplings in Neat Water
  作者：Blanca Inés、Raul SanMartin、María Jesús Moure、Esther Domínguez

  DOI：10.1002/adsc.200900345

  日期：2009.9

  Suzuki–Miyaura biaryl and diarylmethane syntheses via the coupling of arylboronic acids with aryl and arylmethyl bromides are performed in water by means of two new CNC-type palladium pincer complexes. Good to excellent results (including high TON values and extended recycling procedures) are obtained in most cases for a range of electronically dissimilar halides and boronic acids. On the basis of

  水中的铃木-宫浦联芳基和二芳基甲烷通过芳基硼酸与芳基和芳基甲基溴的偶联而合成，是通过两种新型的CNC型钯钳配合物在水中进行的。在大多数情况下，对于一系列电子不同的卤化物和硼酸，可获得良好至优异的结果（包括较高的TON值和扩展的回收程序）。在一系列动力学研究，透射电子显微镜（TEM），汞滴试验和定量中毒实验的基础上，讨论了后者的钯环的实际作用，该环与钯纳米颗粒的形成和活性参与密切相关。
• [EN] COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION
  申请人：TANGO THERAPEUTICS INC

  公开号：WO2021086879A1

  公开（公告）日：2021-05-06

  Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, X5, A, L, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

  根据公式（I）提供化合物及其药学上可接受的盐，以及药物组合物；其中X1、X2、X3、X4、X5、A、L、R1、R2、R5、m和n的定义如本文所述。本发明的化合物被认为对预防和治疗各种疾病条件有用。